Table 3.
Prevalence of ermF and ermB macrolide resistance genes over time
|
ermF % (pos/all samples) |
ermB % (pos/all samples) |
|||||
|---|---|---|---|---|---|---|
| Prevalence | Placebo | Azithromycin | P value | Placebo | Azithromycin | P value |
| Baseline | 44,4 (16/36) | 59,1 (26/44) | 0.261 | 86,1 (31/36) | 97,7 (43/44) | 0.085 |
| M6 | 43,3 (13/30) | 67,6 (23/34) | 0.050 | 80,0 (24/30) | 97,1 (33/34) | 0.029* |
| M12 | 48,1 (13/27) | 68,8 (22/32) | 0.109 | 74,1 (20/27) | 100,0 (32/32) | 0.002* |
*Prevalence of ermB is statistically significant in the Azithromycin group at M6 and M12 compared to the Placebo group (Chi-square, Pearson corrected)